Navigation Links
‘For-profit Dialysis Centers’ in the Spotlight Over Anti-anemia Drug Overdoe

A novel US study has exposed the key drivers behind the functioning of kidney dialysis profit centers across the United States. //Bottom line figures rule the roost, and these centers prescribe overdoses of anti-anemia drugs to realize higher hemoglobin levels in the patients.

The study which is published in the Journal of the American Medical Association, demonstrates how over dosing patients with anti-anemia drugs could endanger their lives. Abnormally high hemoglobin increases the risk of heart attacks, strokes and blood clots.

Healthy kidneys secrete a hormone called erythropoietin which is the catalyst behind the production of red blood cells in the bone marrow. Those patients suffering kidney disease do not produce adequate erythropoietin, therefore there is a dearth of red blood cells, causing anemia.

Epoetin is a drug that acts as a substitute for erythropoietin, and is being prescribed to kidney patients during the course of dialysis. The dosage is altered depending upon their hemoglobin levels and how anemic they are.

Hospitals as well as independently owned profit based units of dialysis across the United States are known to claim reimbursement from the government insurance scheme, Medicare, for the treatment meted out to the patient, which also includes the anti anemia drug epoetin.

According to this study conducted, Epoetin therapy accounted for 1.8 billion dollars of medical drug expenditure in 2004.

The records of 159,522 adult Medicare-eligible, end-stage renal disease patients from the US Renal Data System, undergoing hemodialysis at various centers during November and December 2004 was analyzed using statistical regression models to understand the average epoetin dose and dose adjustments executed by the profit centers. The findings revealed that dosing of the drug epoetin fluctuated according to the status of the dialysis centers, whether they were profit or non-profit center s.

It was also observed that the 106,116 patients who availed treatment from the large for-profit dialysis centers were regularly given the highest doses of epoetin as against 28,199 patients who undertook treatment from nonprofit centers, irrespective of their level of anemia.

It was also observed that a hospital-based centre administered an average dose of 16,188 units per week of epoetin, as against ‘for-profit chain centers’ that administered an average dose of 20,838 units a week. The researchers inferred, "Dialysis facility organizational status and ownership are associated with variation in epoetin dosing in the United States. Different epoetin dosing patterns suggest that large for-profit chain facilities used larger dose adjustments and targeted higher hematocrit levels."

This trend has prompted the FDA to issue warnings for Epoetin against the indiscriminate use of this drug.
SA
'"/>




Related medicine news :

1. Easier Dialysis for Kids
2. More Patients Going In For Home Dialysis
3. Dialysis Clinics Owned By Fresenius Flourishes Due To Its Customers
4. SRN Hospital Dialysis Unit To Resume Function
5. Heparin Based Nanoscale Materials Developed For Dialysis Treatment
6. Exercise Combined with Dialysis Yields Better Results
7. Vitamin E-Coated Dialysis Filters Help Fight Anemia in Hemodialysis Patients
8. Dialysis Patients With Metabolic Syndrome Show Increased Risk for Heart Disease
9. Dialysis Trust Set Up in Bangalore by End-stage Kidney Patients
10. Childhood Obesity Vs Malnutrition- A Spotlight On WHO Obesity Measurement For Kids
11. Spotlight on Aids-prevention
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/11/2016)... , ... February 11, 2016 , ... ... healthcare industry, ranked among the top five firms in the “2015/2016 Best in ... Implementation Support and Staffing. KLAS is a research and insights firm on a ...
(Date:2/11/2016)... FL (PRWEB) , ... February 11, 2016 , ... ... and advocates will discuss how to improve care by making data on heart ... heart disease. The Summit on Transparency and Public Reporting of Pediatric and Congenital ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... and Reconstructive Surgery, Dallas plastic surgeon , Dr. Rod J. Rohrich, and ... surgery . Dr. Rohrich outlines recommendations for rhinoplasty surgeons when addressing this vital ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... clinical decision support technology, with highly adaptable algorithms, has been updated to help ... has signs and symptoms consistent with Zikas and a travel history to affected ...
(Date:2/11/2016)... ... February 11, 2016 , ... "What holds you ... Ray Clarke poses a question as a challenge for his readers to examine ... in the Being" (published by Partridge Singapore), Clarke explores the subject with more ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... -- Governor Andrew M. Cuomo today announced a major expansion ... Western New York . This announcement, made ... includes a major expansion of Athenex,s North American headquarters ... , as well as the creation of a state-of-the-art, ... . The combined projects are expected to yield ...
(Date:2/11/2016)... -- Potrero Medical, Inc., the developer of the Accuryn™ critical ... George M. Rapier, III , MD, to its Board ... WellMed is one of the nation,s largest physician owned practice ... Texas and Florida ... internal medicine practice, he has been instrumental to the company,s ...
(Date:2/11/2016)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), the leading ... birth tissues, human skin and bone, and patent-protected processes ... and therapies, announced today that it will present at ... New York , NY.  Parker H. ... , Chief Financial Officer and Chris Cashman , ...
Breaking Medicine Technology: